{"filing": {"accession": "0001493152-26-049444", "cik": "0001534248", "ticker": "CMMB", "company_name": "Chemomab Therapeutics Ltd.", "form_type": "DEFM14A", "filing_type": "DEFM14A", "filing_date": "2026-10-30", "accepted_datetime": null, "acceptance_datetime": null, "accepted_at": null, "primary_doc_url": "https://www.sec.gov/Archives/edgar/data/1534248/000149315226049444/0001493152-26-049444-index.htm", "filing_url": "https://www.sec.gov/Archives/edgar/data/1534248/000149315226049444/0001493152-26-049444-index.htm", "period_of_report": null}, "html_url": "/api/filings/000149315226049444/stream", "exhibits": [], "sections": [], "tables": [{"table_index": 0, "table_type": "text", "caption": null, "header_text": "\u2610Preliminary\n Proxy Statement"}, {"table_index": 1, "table_type": "text", "caption": null, "header_text": "\u2612No\n fee required."}, {"table_index": 2, "table_type": "text", "caption": null, "header_text": "\u2610Fee\n paid previously with preliminary materials."}, {"table_index": 7, "table_type": "text", "caption": null, "header_text": "\u25cfeach\n outstanding share of Scipher common stock, par value $0.001 per share, and each outstanding share of Scipher preferred stock, par\n value $0.001 per share (collectively, the \u201cScipher Capital Sto"}, {"table_index": 10, "table_type": "text", "caption": null, "header_text": "/s/\n Dr. Nissim Darvish"}, {"table_index": 12, "table_type": "text", "caption": null, "header_text": "(1)To\n consider and vote upon a proposal to approve and adopt the Agreement and Plan of Merger, dated as of July 7, 2026, by and among Chemomab\n Israel, Snowdrift Parent Corporation (\u201cChemomab Parent\u201d"}, {"table_index": 14, "table_type": "text", "caption": null, "header_text": "By\n Order of the Chemomab Israel Board of Directors"}, {"table_index": 17, "table_type": "text", "caption": null, "header_text": "Page"}, {"table_index": 23, "table_type": "financial", "caption": null, "header_text": "\u25cfThelikelihood of the satisfaction of certain conditions to the completion of the Merger, the Domestication Merger and the Concurrent\n PIPE Investment, and whether and when the Transactions will be co"}, {"table_index": 28, "table_type": "text", "caption": null, "header_text": "\u25cfa\n proxy statement of Chemomab Israel used to solicit proxies for its Meeting; and"}, {"table_index": 29, "table_type": "text", "caption": null, "header_text": "Proposal\n NumberProposal\n DescriptionVote\n Required for ApprovalEffect\n of AbstentionsEffect\n of Broker Non-Votes"}, {"table_index": 32, "table_type": "text", "caption": null, "header_text": "\u25cfMilestone\n 1: The earlier to occur of (a) the initiation of a Phase 3 clinical trial with respect\n to nebokitug in the indication of primary sclerosing cholangitis (\u201cPSC\u201d),\n or (b) the occurrence of "}, {"table_index": 34, "table_type": "text", "caption": null, "header_text": "NameCurrent\n Principal Affiliation"}, {"table_index": 36, "table_type": "text", "caption": null, "header_text": "NameCombined\n Company Position(s)Current\n Position(s)"}, {"table_index": 37, "table_type": "text", "caption": null, "header_text": "\u25cf\u201cFOR\u201d\n the Merger Proposal;"}, {"table_index": 44, "table_type": "text", "caption": null, "header_text": "\u25cfall\n 2026 Notes (issued under the 2026 Convertible Note Purchase Agreement dated March 5, 2026,\n as amended on June 23, 2026) will be automatically converted into Scipher Merger Shares (shares\n of Ch"}, {"table_index": 46, "table_type": "text", "caption": null, "header_text": "\u25cfEach\n party has agreed to operate its business in the ordinary course prior to the Closing (with\n certain exceptions) and not to take certain specified actions without the prior written consent\n of t"}, {"table_index": 49, "table_type": "text", "caption": null, "header_text": "\u25cfThe\n Allocation Percentages are not adjustable based on market price, and the relative percentage\n ownership of Chemomab Israel shareholders and former Scipher securityholders in the Combined\n Compan"}, {"table_index": 52, "table_type": "financial", "caption": null, "header_text": "202520242023Six months endedJune 30, 2026Six months endedJune 30, 2025"}, {"table_index": 53, "table_type": "financial", "caption": null, "header_text": "As ofJune 30, 2026As ofDecember 31, 2025As ofDecember 31, 2024"}, {"table_index": 55, "table_type": "financial", "caption": null, "header_text": "Six Months EndedYears Ended December 31,"}, {"table_index": 56, "table_type": "financial", "caption": null, "header_text": "As ofJune 30, 2026As ofDecember 31, 2025As ofDecember 31, 2024"}, {"table_index": 58, "table_type": "financial", "caption": null, "header_text": "Six Months Ended June 30, 2026Year Ended December 31, 2025"}, {"table_index": 59, "table_type": "financial", "caption": null, "header_text": "As ofJune 30, 2026"}, {"table_index": 62, "table_type": "text", "caption": null, "header_text": "\u25cfThe\n Allocation Percentages are not adjustable based on the market price of Chemomab Israel Shares,\n so the merger consideration at the Closing may have a greater or lesser value than at the\n time th"}, {"table_index": 63, "table_type": "financial", "caption": null, "header_text": "\u25cfChemomab\n Israel has a limited operating history, has never generated product revenue, and may never\n become profitable."}, {"table_index": 65, "table_type": "text", "caption": null, "header_text": "\u25cfClinical\n drug development is lengthy, complex and expensive, with an uncertain outcome, and Chemomab\n Israel may never obtain regulatory approval to market nebokitug or any other product candidate."}, {"table_index": 66, "table_type": "text", "caption": null, "header_text": "\u25cfChemomab\n Israel has a limited operating history and funding, which may make it difficult to evaluate\n its prospects and likelihood of success."}, {"table_index": 67, "table_type": "text", "caption": null, "header_text": "\u25cfIf\n Chemomab Israel is unable to protect its patents or other proprietary rights, or if Chemomab\n Israel infringes the patents or other proprietary rights of others, its competitiveness and\n business"}, {"table_index": 68, "table_type": "text", "caption": null, "header_text": "\u25cfThe\n regulatory approval processes of the FDA and comparable foreign authorities are lengthy,\n time consuming and inherently unpredictable, and if Chemomab Israel is ultimately unable\n to obtain regu"}, {"table_index": 70, "table_type": "text", "caption": null, "header_text": "\u25cfIf\n Chemomab Israel does not achieve its projected development and commercialization goals in\n the timeframes it announces and expects, the commercialization of its product candidates\n may be delayed"}, {"table_index": 71, "table_type": "financial", "caption": null, "header_text": "\u25cfConditions\n in Israel could materially and adversely affect Chemomab Israel\u2019s business."}, {"table_index": 73, "table_type": "financial", "caption": null, "header_text": "\u25cfScipher\n has incurred significant losses since inception, had an accumulated deficit of $328.4\n million as of June 30, 2026, and may never achieve or maintain profitability."}, {"table_index": 75, "table_type": "text", "caption": null, "header_text": "\u25cfScipher\n is subject to extensive healthcare laws and regulations, including fraud and abuse, data\n privacy and security (including HIPAA and state genetic-privacy laws) and reimbursement rules,\n and "}, {"table_index": 77, "table_type": "financial", "caption": null, "header_text": "\u25cfChemomab\n Israel has incurred and expects to continue to incur significant expenses related to the\n proposed Merger with Scipher, even if the Merger is not consummated."}, {"table_index": 80, "table_type": "text", "caption": null, "header_text": "\u25cfthe\n announcement of the Merger Agreement or the pendency of the Merger and the other transactions\n contemplated by the Merger Agreement;"}, {"table_index": 81, "table_type": "text", "caption": null, "header_text": "\u25cfthe\n announcement of the Merger Agreement or the pendency of the Merger and the other transactions\n contemplated by the Merger Agreement;"}, {"table_index": 83, "table_type": "text", "caption": null, "header_text": "\u25cfany\n change in U.S. generally accepted accounting principles or applicable law, or the interpretation\n thereof; and"}, {"table_index": 84, "table_type": "text", "caption": null, "header_text": "\u25cfthe\n Combined Company does not achieve the perceived benefits of the Merger as rapidly or to the\n extent anticipated by financial or industry analysts;"}, {"table_index": 253, "table_type": "text", "caption": null, "header_text": "\u25cfidentifying,\n recruiting, integrating, retaining, and motivating employees;"}, {"table_index": 254, "table_type": "financial", "caption": null, "header_text": "\u25cfthe\n level of demand for our solutions, which may vary significantly;"}, {"table_index": 256, "table_type": "text", "caption": null, "header_text": "\u25cfour\n execution of any strategic transactions, including acquisitions, collaborations, licenses\n or similar arrangements, and the timing and amount of payments we may make or receive in\n connection wi"}, {"table_index": 262, "table_type": "text", "caption": null, "header_text": "\u25cfincrease\n our sales and marketing efforts to drive market adoption of our current solutions and address\n competitive developments;"}, {"table_index": 264, "table_type": "financial", "caption": null, "header_text": "\u25cfacquire,\n license, or invest in our existing and future technologies;"}, {"table_index": 265, "table_type": "financial", "caption": null, "header_text": "\u25cfthe\n cost of development and commercialization activities, including marketing and sales, for\n our solutions;"}, {"table_index": 273, "table_type": "text", "caption": null, "header_text": "\u25cfThe\n initiation and completion of validation studies and clinical trials may be prevented, delayed,\n or halted for numerous reasons, including related to the following:"}, {"table_index": 275, "table_type": "text", "caption": null, "header_text": "\u25cfthe\n inability to generate sufficient in vitro or in vivo data to support the initiation or continuation\n of validation studies or clinical trials;"}, {"table_index": 277, "table_type": "text", "caption": null, "header_text": "\u25cfchanges\n in the standard of care on which a clinical development plan was based, which may require\n new or additional clinical trials;"}, {"table_index": 284, "table_type": "text", "caption": null, "header_text": "\u25cfthe\n federal Anti-Kickback Statute (the \u201cAKS\u201d), which prohibits, among other\n things, knowingly and willfully soliciting, receiving, offering, or paying any remuneration\n (including any kickback, bri"}, {"table_index": 286, "table_type": "exhibit_index", "caption": null, "header_text": "\u25cfthe\n federal False Claims Act (the \u201cFCA\u201d), which imposes civil and criminal\n liability on individuals or entities that knowingly submit false or fraudulent claims for\n payment to the government or kn"}, {"table_index": 288, "table_type": "text", "caption": null, "header_text": "\u25cffederal\n and state consumer protection and unfair competition laws, which broadly regulate marketplace\n activities and activities that potentially harm consumers; and"}, {"table_index": 299, "table_type": "financial", "caption": null, "header_text": "\u25cfrestrictions\n on operations of our laboratories;"}, {"table_index": 306, "table_type": "text", "caption": null, "header_text": "\u25cfany\n of our patents, or any of our pending patent applications, if issued, will include claims\n having a scope sufficient to protect our solutions;"}, {"table_index": 309, "table_type": "text", "caption": null, "header_text": "\u25cfthe\n scope of rights granted under the license agreement;"}, {"table_index": 311, "table_type": "text", "caption": null, "header_text": "\u25cfour\n diligence and other obligations under the license agreement;"}, {"table_index": 320, "table_type": "text", "caption": null, "header_text": "\u25cfcollaborators\n have significant discretion in determining the efforts and resources that they will apply\n to these collaborations and they may not devote the level of effort or resources we expect;"}, {"table_index": 323, "table_type": "text", "caption": null, "header_text": "\u25cfauthorize\n our board of directors to issue shares of preferred stock and determine the price and other\n terms of those shares, including preferences and voting rights, without shareholder approval;"}, {"table_index": 325, "table_type": "text", "caption": null, "header_text": "\u25cfany\n derivative action or proceeding brought on our behalf;"}, {"table_index": 333, "table_type": "text", "caption": null, "header_text": "\u25cf\u201cFOR\u201d\n the Merger Proposal"}, {"table_index": 335, "table_type": "text", "caption": null, "header_text": "\u25cfProposal\n No. 1 - The Merger Proposal requires the affirmative vote of the majority of the Chemomab Israel Shares present in person or represented\n by proxy. Abstentions and broker non-votes will hav"}, {"table_index": 344, "table_type": "text", "caption": null, "header_text": "\u25cfthe\n Chemomab Israel Board believes that a \u201cgo it alone\u201d scenario was not without\n significant risk and dilution to the Chemomab Israel shareholders, taking into account Chemomab\n Israel\u2019s business, "}, {"table_index": 346, "table_type": "text", "caption": null, "header_text": "\u25cfthe\n risks associated with continuing to operate Chemomab Israel on a stand-alone basis, including\n the substantial capital that would be required to initiate and complete the contemplated\n Phase 3 c"}, {"table_index": 347, "table_type": "text", "caption": null, "header_text": "\u25cfthe\n proposed valuation and equity split for the Combined Company and the allocation of\n ownership between Chemomab Israel\u2019s shareholders and Scipher\u2019s stockholders,\n which were negotiated over sever"}, {"table_index": 348, "table_type": "financial", "caption": null, "header_text": "\u25cfthe\n substantial expenses to be incurred by Chemomab Israel in connection with the Merger;"}, {"table_index": 350, "table_type": "text", "caption": null, "header_text": "\u25cfthe\n risk that the Merger might not be consummated in a timely manner or at all, and the potential\n adverse effect of the public announcement of the Merger, or any delay in or failure to complete\n th"}, {"table_index": 351, "table_type": "financial", "caption": null, "header_text": "($\n in thousands)2026202720282029203020312032203320342035203620372038"}, {"table_index": 355, "table_type": "text", "caption": null, "header_text": "\u25cfreviewed\n a draft dated July 2, 2026 of the Merger Agreement;"}, {"table_index": 357, "table_type": "text", "caption": null, "header_text": "\u25cfconsidered\n the financial terms of certain initial public offerings that Oppenheimer deemed relevant in evaluating Scipher;"}, {"table_index": 359, "table_type": "text", "caption": null, "header_text": "\u25cfSOPHiA\n GENETICS SA"}, {"table_index": 361, "table_type": "text", "caption": null, "header_text": "\u25cfInsight\n Molecular Diagnostics, Inc."}, {"table_index": 362, "table_type": "text", "caption": null, "header_text": "\u25cfCapsoVision,\n Inc."}, {"table_index": 363, "table_type": "text", "caption": null, "header_text": "Date\n announcedAcquirerTarget"}, {"table_index": 365, "table_type": "financial", "caption": null, "header_text": "\u25cfthe\n potential opportunity to combine Scipher\u2019s immunology precision medicine platform,\n its proprietary RA data assets, its AI-enabled Network Medicine capabilities, and PrismRA\u00ae,\n a treatment respo"}, {"table_index": 366, "table_type": "financial", "caption": null, "header_text": "\u25cfthe\n determination that the expected relative percentage ownership of Chemomab Israel\u2019s\n shareholders and Scipher\u2019s stockholders in the Combined Company was appropriate based,\n in the judgment of the"}, {"table_index": 367, "table_type": "text", "caption": null, "header_text": "\u25cfthe\n belief that the other terms of the Merger Agreement, including the parties\u2019 representations,\n warranties and covenants, and the conditions to their respective obligations, were reasonable\n in li"}, {"table_index": 369, "table_type": "text", "caption": null, "header_text": "\u25cfthe\n support agreements, pursuant to which certain directors, officers and shareholders of Chemomab\n Israel have agreed, solely in their capacity as shareholders of Chemomab Israel, respectively,\n to"}, {"table_index": 370, "table_type": "financial", "caption": null, "header_text": "\u25cfthe\n possibility that the Merger might not be completed and the potential adverse effect of the\n public announcement of the Merger on the reputation of Scipher and the ability of\n Scipher to obtain f"}, {"table_index": 372, "table_type": "text", "caption": null, "header_text": "\u25cfby\n virtue of the Merger without any further action on the part of the parties to the Merger\n Agreement, all outstanding Notes issued under that certain Convertible Note Purchase and\n Investment Obli"}, {"table_index": 374, "table_type": "text", "caption": null, "header_text": "\u25cf\u201cAggregate\n Valuation\u201d means the sum of (i) the Scipher Valuation and (ii) the Chemomab Valuation."}, {"table_index": 376, "table_type": "text", "caption": null, "header_text": "\u25cffinancial\n institutions or financial services entities;"}, {"table_index": 378, "table_type": "text", "caption": null, "header_text": "\u25cfpersons\n that actually or constructively own five percent or more (by vote or value) of the outstanding\n Chemomab Israel Shares prior to the Domestication Merger or of the outstanding Chemomab Parent"}, {"table_index": 380, "table_type": "financial", "caption": null, "header_text": "\u25cfan\n individual citizen or resident of the United States,"}, {"table_index": 385, "table_type": "financial", "caption": null, "header_text": "\u25cfthe\n U.S. Holder\u2019s gain, if any, would generally be allocated ratably over the U.S. Holder\u2019s\n holding period for such U.S. Holder\u2019s Chemomab Israel Shares;"}, {"table_index": 389, "table_type": "financial", "caption": null, "header_text": "\u25cfthe\n gain is effectively connected with a U.S. trade or business of such Non-U.S. Holder (and,\n if an applicable treaty so provides, is also attributable to a permanent establishment maintained\n by s"}, {"table_index": 393, "table_type": "financial", "caption": null, "header_text": "\u25cfsuch\n Non-U.S. Holder is an individual who was present in the United States for 183 days or more\n in the taxable year of such disposition and certain other requirements are met, in which\n case any ga"}, {"table_index": 399, "table_type": "text", "caption": null, "header_text": "\u25cfby\n virtue of the Merger without any further action on the part of the parties to the Merger Agreement, all outstanding Notes issued\n under that certain Convertible Note Purchase and Investment Oblig"}, {"table_index": 402, "table_type": "text", "caption": null, "header_text": "\u25cf\u201cAggregate\n Valuation\u201d means the sum of (i) the Scipher Valuation and (ii) the Chemomab Valuation."}, {"table_index": 405, "table_type": "text", "caption": null, "header_text": "Scipher\n componentIllustrative\n reference value"}, {"table_index": 408, "table_type": "financial", "caption": null, "header_text": "\u25cfcorporate\n organization and power, and similar corporate matters;"}, {"table_index": 410, "table_type": "text", "caption": null, "header_text": "\u25cfChemomab\n Israel has agreed to use commercially reasonable efforts to conduct its business and operations in the ordinary course of business\n and in material compliance with all applicable law and re"}, {"table_index": 411, "table_type": "text", "caption": null, "header_text": "\u25cfThe\n representations and warranties of Scipher shall be true and correct as of the Closing Date (or such other date to which they refer)\n except to the extent that such failure does not result in a S"}, {"table_index": 413, "table_type": "exhibit_index", "caption": null, "header_text": "\u25cfThe\n required stockholders of Scipher shall have delivered Lock-Up Agreements."}, {"table_index": 414, "table_type": "text", "caption": null, "header_text": "\u25cfThe\n representations and warranties of Chemomab Israel, Chemomab Parent, Merger Sub and Domestication Merger Sub shall be true and correct\n as of the Closing Date (or such other date to which they re"}, {"table_index": 416, "table_type": "exhibit_index", "caption": null, "header_text": "\u25cfScipher\n shall have received documentation evidencing the termination of the Chemomab Israel Employee Plan qualified under Section 401(k)\n of the Code."}, {"table_index": 417, "table_type": "text", "caption": null, "header_text": "\u25cfmutual\n consent of Chemomab Israel and Scipher;"}, {"table_index": 419, "table_type": "exhibit_index", "caption": null, "header_text": "\u25cfby\n either Chemomab Israel or Scipher if a court of competent jurisdiction or other Governmental Authority shall have issued a final\n and non-appealable Order, or shall have taken any other action, h"}, {"table_index": 422, "table_type": "text", "caption": null, "header_text": "\u25cfMilestone\n 1: The earlier to occur of (a) the initiation of a Phase 3 clinical trial with respect to nebokitug in the indication of PSC,\n or (b) the occurrence of a disposition of nebokitug in the in"}, {"table_index": 426, "table_type": "text", "caption": null, "header_text": "\u25cfall\n outstanding notes issued under that certain Convertible Note Purchase Agreement, dated February 28, 2025, which was further amended\n and restated pursuant to the 2026 CNPA (the \u201c2025 Notes\u201d), wi"}, {"table_index": 437, "table_type": "text", "caption": null, "header_text": "Gross Proceeds from Concurrent PIPE Investment$30,000,000$40,000,000$50,000,000"}, {"table_index": 438, "table_type": "text", "caption": null, "header_text": "Gross Proceeds from Concurrent PIPE Investment$30,000,000$40,000,000$50,000,000"}, {"table_index": 440, "table_type": "text", "caption": null, "header_text": "\u25cfthe\n Class I directors will be Stefan Krieglstein, MS and Brett Blackman, Ph.D., and their terms will expire at the annual\n meeting of stockholders to be held in 2027;"}, {"table_index": 443, "table_type": "text", "caption": null, "header_text": "Fiscal\n YearOptions\n GrantedBurn\n Rate(1)"}, {"table_index": 445, "table_type": "text", "caption": null, "header_text": "\u25cfStock\n Options. The Administrator may grant incentive stock options and nonstatutory stock options (\u201cNSOs\u201d). The exercise\n price of each option must be at least 100% of the fair market value of our C"}, {"table_index": 447, "table_type": "text", "caption": null, "header_text": "\u25cfRestricted\n Stock Unit Awards. The Administrator may grant contractual rights to receive shares of Chemomab Parent Common Stock (or cash or a\n combination) in the future upon vesting, generally in ex"}, {"table_index": 450, "table_type": "text", "caption": null, "header_text": "\u25cfSection\n 409A. Awards are intended to be exempt from, or to comply with, Section 409A of the Code, and the 2026 Plan includes customary provisions\n (including a six-month-and-one-day delay for certai"}, {"table_index": 452, "table_type": "exhibit_index", "caption": null, "header_text": "\u25cfNon-Exempt\n Employees. Consistent with the Fair Labor Standards Act, an option or SAR granted to a non-exempt employee will generally not be\n exercisable until at least six months after the grant dat"}, {"table_index": 453, "table_type": "financial", "caption": null, "header_text": "TermMeaning"}, {"table_index": 455, "table_type": "text", "caption": null, "header_text": "TermMeaning"}, {"table_index": 458, "table_type": "text", "caption": null, "header_text": "Plan CategoryNumber of Securities to be Issued Upon Exercise of Outstanding Options, Warrants, and RightsWeighted-Average Exercise Price of Outstanding Options, Warrants, and RightsNumber of Securitie"}, {"table_index": 460, "table_type": "text", "caption": null, "header_text": "\u25cfDuration\n for which the reserved shares are expected to last. Based on our anticipated participation rate and historical usage under any predecessor\n arrangements, we expect that the shares initially"}, {"table_index": 463, "table_type": "text", "caption": null, "header_text": "\u25cfPer-offering\n share limit. Before an offering commences, the Administrator may determine to set a limit on the number of shares of Chemomab\n Parent Common Stock that each eligible employee may purcha"}, {"table_index": 465, "table_type": "text", "caption": null, "header_text": "\u25cfNo\n Fractional Shares; Compliance Delay. No fractional shares will be issued unless the applicable offering specifically provides for\n them. If, as of a purchase date, the shares issuable under the 2"}, {"table_index": 467, "table_type": "text", "caption": null, "header_text": "TermMeaning"}, {"table_index": 490, "table_type": "text", "caption": null, "header_text": "\u25cfHuman\n hepatic stellate cells demonstrated reduced transition to myofibroblasts following incubation of nebokitug with CCL24."}, {"table_index": 493, "table_type": "text", "caption": null, "header_text": "\u25cfNebokitug\n reduces SSc serum-induced dermal fibroblast activation and transition to myofibroblasts and interferes with endothelial cell activation."}, {"table_index": 497, "table_type": "text", "caption": null, "header_text": "Preclinical\n findingsObservation"}, {"table_index": 511, "table_type": "financial", "caption": null, "header_text": "\u25cfChemomab\n Israel will be required to pay TASMC non-refundable and non-creditable milestone payments\n of up to (i) $300,000 upon the submission of an NDA, BLA or equivalent for each of the licensed\n p"}, {"table_index": 513, "table_type": "text", "caption": null, "header_text": "\u25cfcompletion\n of preclinical laboratory tests, animal studies and formulation studies in compliance with\n the FDA\u2019s Good Laboratory Practice regulations;"}, {"table_index": 515, "table_type": "text", "caption": null, "header_text": "\u25cfcompletion\n of all manufacturing requirements to ensure robust manufacturing process, and product quality\n and safety as per Good Manufacturing Practice, or cGMP guidelines;"}, {"table_index": 517, "table_type": "exhibit_index", "caption": null, "header_text": "\u25cfPhase\n 1:The drug or biologic is initially introduced into healthy human subjects or patients\n with the target disease or condition and tested for safety, dosage tolerance, absorption,\n metabolism, d"}, {"table_index": 523, "table_type": "text", "caption": null, "header_text": "\u25cfRestrictions on the marketing\n or manufacturing of the product, complete withdrawal of the product from the market or product recalls;"}, {"table_index": 525, "table_type": "text", "caption": null, "header_text": "\u25cfThe\n federal Anti-Kickback Statute, or AKS, which makes it illegal for any person, including a\n prescription drug manufacturer (or a party acting on its behalf) to knowingly and willfully\n solicit, r"}, {"table_index": 527, "table_type": "text", "caption": null, "header_text": "\u25cfThe\n federal Physician Payments Sunshine Act, created under Patient Protection and Affordable\n Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively,\n the "}, {"table_index": 534, "table_type": "financial", "caption": null, "header_text": "\u25cfexpenses\n incurred under agreements with contract research organizations or contract manufacturing organizations, as well as investigative\n sites and consultants that conduct Chemomab Israel\u2019s clinic"}, {"table_index": 536, "table_type": "financial", "caption": null, "header_text": "Six months ended June 30,Increase/(decrease)"}, {"table_index": 537, "table_type": "financial", "caption": null, "header_text": "Year ended December\n 31,"}, {"table_index": 540, "table_type": "financial", "caption": null, "header_text": "Six months ended June 30,Change"}, {"table_index": 542, "table_type": "text", "caption": null, "header_text": "Year ended December 31,"}, {"table_index": 546, "table_type": "financial", "caption": null, "header_text": "\u25cfthe progress and costs\n of its preclinical and clinical trials and other research and development activities;"}, {"table_index": 547, "table_type": "financial", "caption": null, "header_text": "\u25cfthe costs of contracting\n with third parties to provide sales and marketing capabilities for it or establishing such capabilities by itself;"}, {"table_index": 558, "table_type": "text", "caption": null, "header_text": "\u25cfFirst-generation\n approaches, which relied primarily on physiological, genetic or clinical biomarkers to characterize\n disease state or patient status; and"}, {"table_index": 562, "table_type": "financial", "caption": null, "header_text": "\u25cfPreclinical\n partnerships for target discovery, portfolio prioritization and target toxicity assessment;"}, {"table_index": 571, "table_type": "text", "caption": null, "header_text": "1.Large\n RA market opportunity exists with significant unmet need;"}, {"table_index": 593, "table_type": "financial", "caption": null, "header_text": "For\n the Six Months EndedJune\n 30,Change"}, {"table_index": 595, "table_type": "financial", "caption": null, "header_text": "For the Year EndedDecember 31,Change"}, {"table_index": 600, "table_type": "financial", "caption": null, "header_text": "\u25cfthe\n ability to maintain and grow sales of our PrismRA\u00ae diagnostic product, as well as the\n costs associated with conducting clinical studies to demonstrate the utility of our products\n and support r"}, {"table_index": 602, "table_type": "text", "caption": null, "header_text": "Six Months Ended June 30,Year Ended December 31,"}, {"table_index": 606, "table_type": "text", "caption": null, "header_text": "\u25cfprices\n paid for our convertible preferred stock, which had been sold to outside investors in arm\u2019s-length\n transactions, and the rights, preferences, and privileges of convertible preferred stock\n a"}, {"table_index": 608, "table_type": "text", "caption": null, "header_text": "NameAgePosition"}, {"table_index": 612, "table_type": "text", "caption": null, "header_text": "\u25cfappointing,\n determining the compensation of, retaining, overseeing and evaluating the Combined Company\u2019s\n independent registered public accounting firm and any other registered public accounting\n fi"}, {"table_index": 614, "table_type": "exhibit_index", "caption": null, "header_text": "\u25cfreviewing\n the effectiveness of the Combined Company\u2019s overall compensation strategy to assure\n that it promotes stockholder interests and supports our strategic and tactical objectives,\n and that it"}, {"table_index": 615, "table_type": "text", "caption": null, "header_text": "\u25cfreviewing\n and recommending to the Combined Company Board for approval the frequency with which\n the Combined Company conducts an advisory vote on executive compensation, taking into account\n the res"}, {"table_index": 617, "table_type": "text", "caption": null, "header_text": "\u25cfevaluating\n composition, size, organization and governance of the Combined Company Board and its committees\n to ensure that they appropriately reflect the knowledge, skills, integrity, ethics, divers"}, {"table_index": 620, "table_type": "text", "caption": null, "header_text": "Name and Principal PositionYearSalary($)Bonus($)Stock\n Awards(1)($)Option Awards (1)($)Non-equity Incentive Plan CompensationAll\n Other Compensation($)Total($)"}, {"table_index": 625, "table_type": "text", "caption": null, "header_text": "\u25cfat least a majority of the shares held by all shareholders who are not controlling shareholders and do not have a personal interest in such matter, present and voting at such meeting, are voted in fa"}, {"table_index": 627, "table_type": "text", "caption": null, "header_text": "\u25cfsuch majority includes at least a majority of the shares held by shareholders who are not controlling shareholders and shareholders who do not have a personal interest in such compensation policy; or"}, {"table_index": 628, "table_type": "text", "caption": null, "header_text": "\u25cfthe education, skills, experience, expertise and accomplishments of the relevant office holder;"}, {"table_index": 630, "table_type": "text", "caption": null, "header_text": "\u25cfwith regards to variable components:"}, {"table_index": 632, "table_type": "text", "caption": null, "header_text": "\u25cfReginald\n Seeto, M.B.B.S., President & Chief Executive Officer;"}, {"table_index": 634, "table_type": "text", "caption": null, "header_text": "Name and Principal PositionYearSalaryBonusStock\n AwardsOption\n Awards(1)NonqualifiedDeferred CompensationEarningsAll\n Other CompensationTotal"}, {"table_index": 635, "table_type": "text", "caption": null, "header_text": "(1)Reflects the\n aggregate grant date fair value computed in accordance with ASC Topic 718. These amounts do not necessarily correspond to the actual\n value that may be recognized by the named executi"}, {"table_index": 638, "table_type": "text", "caption": null, "header_text": "Option Awards"}, {"table_index": 639, "table_type": "text", "caption": null, "header_text": "(1)Represents\n an option to purchase 70,000 shares of Scipher common stock, granted on May 15, 2025, of which 25% vested on May 15, 2026, the one-year\n anniversary of the vesting commencement date, an"}, {"table_index": 642, "table_type": "text", "caption": null, "header_text": "Name of DirectorFees Earned or Paid in CashAggregate Grant Date Fair Market Value of Option Awards Granted in FY2025Total"}, {"table_index": 644, "table_type": "financial", "caption": null, "header_text": "\u25cfthe amount\n involved exceeded the lesser of (i) $120,000, and (ii) one percent of the average of Chemomab Israel\u2019s or Scipher\u2019s total\n assets at year end for the last two completed fiscal years, and"}, {"table_index": 646, "table_type": "text", "caption": null, "header_text": "202420252026"}, {"table_index": 654, "table_type": "financial", "caption": null, "header_text": "ScipherMedicineCorporationChemomabTherapeutics\n Ltd.TransactionNotesPro Forma"}, {"table_index": 656, "table_type": "financial", "caption": null, "header_text": "ScipherMedicineCorporationChemomabTherapeutics\n Ltd.TransactionPro Forma"}, {"table_index": 658, "table_type": "financial", "caption": null, "header_text": "ScipherMedicineCorporationChemomabTherapeutics Ltd.TransactionPro Forma"}, {"table_index": 662, "table_type": "text", "caption": null, "header_text": "\u25cfEach\n Chemomab Israel ADS outstanding immediately prior to the Domestication (each representing\n 80 Chemomab Israel Shares) will be exchanged, on an assumed one-for-0.187 basis, for\n shares of Chemom"}, {"table_index": 663, "table_type": "text", "caption": null, "header_text": "CommonOwnership"}, {"table_index": 667, "table_type": "financial", "caption": null, "header_text": "\u25cfComposition\n of senior management.Scipher\u2019s executive\n management team will become the executive management team of the Combined Company."}, {"table_index": 669, "table_type": "text", "caption": null, "header_text": "(in thousands)Amount"}, {"table_index": 670, "table_type": "financial", "caption": null, "header_text": "(in thousands)Amount"}, {"table_index": 673, "table_type": "text", "caption": null, "header_text": "Concurrent PIPE Investment commitment$30,000"}, {"table_index": 679, "table_type": "financial", "caption": null, "header_text": "(G)To\n reflect the elimination of Chemomab Israel\u2019s historical equity balances, comprising a reduction of additional paid-in capital\n of $124.2 million and a reduction of accumulated deficit of $115.6"}, {"table_index": 681, "table_type": "financial", "caption": null, "header_text": "(J)To\n reflect the immediate expense recognition of the acquired IPR&D of $6.2 million. Because the acquired IPR&D has no\n alternative future use, the amount of consideration allocated to it is expens"}, {"table_index": 682, "table_type": "text", "caption": null, "header_text": "Six Months EndedYear Ended"}, {"table_index": 707, "table_type": "text", "caption": null, "header_text": "Chemomab\n Parent Stockholder RightsChemomab\n Israel Shareholder Rights"}, {"table_index": 709, "table_type": "text", "caption": null, "header_text": "The\n Amended and Restated Bylaws provide that, except as otherwise required by the Amended and Restated Certificate of Incorporation,\n the Amended and Restated Bylaws, the rules or regulations of any "}, {"table_index": 712, "table_type": "text", "caption": null, "header_text": "Shareholder\n Rights PlansChemomab\n Parent currently has no stockholder rights plan. Chemomab Parent has no present intention to adopt a stockholder rights plan.The\n validity of a shareholder rights pl"}, {"table_index": 714, "table_type": "financial", "caption": null, "header_text": "Approval\n of M&A TransactionsThe\n DGCL generally requires that a merger and consolidation, or sale, lease, or exchange of all or substantially all of a corporation\u2019s\n assets be approved by the board o"}, {"table_index": 715, "table_type": "text", "caption": null, "header_text": "Number\n of DirectorsThe\n Amended and Restated Certificate of Incorporation will provide that the number of directors shall be determined by Chemomab Parent\u2019s\n board of directors from time to time.Chem"}, {"table_index": 717, "table_type": "text", "caption": null, "header_text": "Election\n of DirectorsThe\n Amended and Restated Bylaws will provide that directors will be elected by a plurality of the votes cast with respect to that director-nominee\u2019s\n election at a meeting for t"}, {"table_index": 719, "table_type": "text", "caption": null, "header_text": "Removal\n of DirectorsThe\n Amended and Restated Certificate of Incorporation will provide that the board of directors or any individual director may be removed\n from office only for cause and only by t"}, {"table_index": 726, "table_type": "text", "caption": null, "header_text": "(g)\n any additional information as may reasonably be required by Chemomab Parent to determine whether the proposed nominee\n is qualified to serve as a director of Chemomab Parent under the Amended and"}, {"table_index": 731, "table_type": "text", "caption": null, "header_text": "Special\n Meetings of ShareholdersThe\n Amended and Restated Certificate of Incorporation will provide that special meetings of stockholders for any purpose or purposes\n may be called at any time only b"}, {"table_index": 738, "table_type": "text", "caption": null, "header_text": "In\n addition, under the Israeli Companies Law, each shareholder has a duty to act in good faith toward the company and other shareholders\n and to refrain from abusing his or her power in the company, "}, {"table_index": 740, "table_type": "text", "caption": null, "header_text": "Internal\n AuditorThere\n is no requirement under the DGCL for a corporation to appoint an Internal Auditor.According\n to the Israeli Companies Law, the board of directors of a public company shall appo"}, {"table_index": 742, "table_type": "text", "caption": null, "header_text": "In\n addition, the DGCL provides that, unless the certificate of incorporation provides otherwise,\n stockholders of a surviving corporation do not have the right to dissent from a plan of merger\n if th"}, {"table_index": 745, "table_type": "text", "caption": null, "header_text": "\u25cbeach\n person or entity known by Scipher to beneficially own 5% or more of its outstanding common stock;"}, {"table_index": 746, "table_type": "text", "caption": null, "header_text": "Name\n of Beneficial OwnerShares\n of Scipher Common Stock Beneficially OwnedPercentage"}, {"table_index": 747, "table_type": "text", "caption": null, "header_text": "(1)Consists\n of (i) 687,163 shares issuable upon conversion of the Series B Preferred Stock held by Northpond Ventures, LP (\u201cNorthpond\n Fund\u201d), (ii) 1,019,880 and 280,639 shares issuable upon conversi"}, {"table_index": 749, "table_type": "text", "caption": null, "header_text": "\u25cfeach\n person or entity known by Chemomab Israel to beneficially own 5% or more of its outstanding shares;"}, {"table_index": 751, "table_type": "text", "caption": null, "header_text": "NAME\nOF BENEFICIAL OWNERTotal Beneficial Ownership (ADSs)Percentage of ADSs Beneficially Owned"}, {"table_index": 752, "table_type": "text", "caption": null, "header_text": "(1)Such\n amount as reported by HBM Healthcare Investments (Cayman) Ltd. (\u201cHBM\u201d) in a Schedule 13D/A filed with the SEC on September\n9, 2026. Voting and investment power over the Chemomab Israel Shares"}, {"table_index": 754, "table_type": "text", "caption": null, "header_text": "\u25cfeach\n person, or group of affiliated persons, expected by Chemomab Israel and Scipher to become the beneficial owner of more than 5% of\n the outstanding common stock of the Combined Company;"}, {"table_index": 755, "table_type": "text", "caption": null, "header_text": "Name of Beneficial OwnerShares of Scipher Common Stock Beneficially OwnedPercentage"}, {"table_index": 756, "table_type": "text", "caption": null, "header_text": "(1)Consists\n of (i) 406,400 and 1,383,826 shares of common stock to be held by Northpond Capital, LP (\u201cNorthpond Capital\u201d)\n and Northpond SM Holdings, LLC, respectively (in each case inclusive of PIPE"}, {"table_index": 763, "table_type": "financial", "caption": null, "header_text": "Page"}, {"table_index": 764, "table_type": "financial", "caption": null, "header_text": "Page"}, {"table_index": 765, "table_type": "financial", "caption": null, "header_text": "Page"}, {"table_index": 766, "table_type": "financial", "caption": null, "header_text": "Page"}, {"table_index": 769, "table_type": "financial", "caption": null, "header_text": "Page"}, {"table_index": 772, "table_type": "financial", "caption": null, "header_text": "December 31,December 31,"}, {"table_index": 776, "table_type": "text", "caption": null, "header_text": ""}, {"table_index": 778, "table_type": "financial", "caption": null, "header_text": "Note202520242023"}, {"table_index": 783, "table_type": "text", "caption": null, "header_text": "NumberUSDNumberUSDUSDUSDUSD"}, {"table_index": 787, "table_type": "financial", "caption": null, "header_text": "202520242023"}, {"table_index": 806, "table_type": "text", "caption": null, "header_text": "%"}, {"table_index": 827, "table_type": "text", "caption": null, "header_text": "December 31,December 31,"}, {"table_index": 828, "table_type": "financial", "caption": null, "header_text": "December 31,December 31,"}, {"table_index": 830, "table_type": "text", "caption": null, "header_text": "December 31,December 31,"}, {"table_index": 833, "table_type": "text", "caption": null, "header_text": "(a)$100\n thousands upon submission of a New Drug Application (\u201cNDA\u201d), Biological License Application (\u201cBLA\u201d) or equivalent\n for each Licensed Product to the United States Food and Drug Administration "}, {"table_index": 845, "table_type": "text", "caption": null, "header_text": "1.On\n March 15, 2021, the Company entered into Securities Purchase Agreements pursuant to which the Company sold 654,818 ADSs in a private\n placement transaction. The Private Placement closed on March"}, {"table_index": 847, "table_type": "text", "caption": null, "header_text": "6.On\n July 25, 2024, the Company entered into Securities Purchase Agreements with existing and new investors of the Company (the \u201cPurchasers\u201d),\n pursuant to which the Company agreed to sell $10.0 mill"}, {"table_index": 852, "table_type": "financial", "caption": null, "header_text": "Year endedYear endedYear ended"}, {"table_index": 856, "table_type": "text", "caption": null, "header_text": "Weighted averageexercise priceNumberof optionsWeightedaverageremaining contractual life (in years)Weightedaverageexercise priceNumberof optionsWeightedaverageremaining contractual life (in years)"}, {"table_index": 857, "table_type": "text", "caption": null, "header_text": "Weighted averageexercise priceNumberof optionsWeightedaverageremaining contractual life (in years)Weightedaverageexercise priceNumberof optionsWeightedaverageremaining contractual life (in years)"}, {"table_index": 859, "table_type": "text", "caption": null, "header_text": "Number of RSAs"}, {"table_index": 863, "table_type": "text", "caption": null, "header_text": "2025 grants of Options"}, {"table_index": 864, "table_type": "text", "caption": null, "header_text": "(a)The\n weighted average share price is based on the Company\u2019s Ordinary Share closing price on the stock exchange as at the grant date"}, {"table_index": 866, "table_type": "financial", "caption": null, "header_text": "Year endedYear endedYear ended"}, {"table_index": 867, "table_type": "financial", "caption": null, "header_text": "Year endedYear endedYear ended"}, {"table_index": 874, "table_type": "financial", "caption": null, "header_text": "December 31,December 31,"}, {"table_index": 878, "table_type": "financial", "caption": null, "header_text": "USD thousands"}, {"table_index": 881, "table_type": "financial", "caption": null, "header_text": "2025 Amount%"}, {"table_index": 882, "table_type": "financial", "caption": null, "header_text": "December 31,December 31,"}, {"table_index": 885, "table_type": "text", "caption": null, "header_text": "202520242023"}, {"table_index": 888, "table_type": "financial", "caption": null, "header_text": "December 31,December 31,"}, {"table_index": 891, "table_type": "financial", "caption": null, "header_text": "Year endedYear endedYear ended"}, {"table_index": 892, "table_type": "text", "caption": null, "header_text": "Year endedYear endedYear ended"}, {"table_index": 894, "table_type": "text", "caption": null, "header_text": "Year endedYear endedYear ended"}, {"table_index": 896, "table_type": "financial", "caption": null, "header_text": "Page"}, {"table_index": 898, "table_type": "financial", "caption": null, "header_text": "June 30,December 31,"}, {"table_index": 901, "table_type": "financial", "caption": null, "header_text": "Six monthsThree monthsSix monthsThree months"}, {"table_index": 904, "table_type": "text", "caption": null, "header_text": "NumberUSD(*)(**)USDUSDUSD"}, {"table_index": 908, "table_type": "financial", "caption": null, "header_text": "OrdinaryShares (*)(**)Additionalpaid incapitalAccumulatedDeficitTotalShareholders\u2019 equity"}, {"table_index": 912, "table_type": "financial", "caption": null, "header_text": "Six monthsSix months"}, {"table_index": 919, "table_type": "financial", "caption": null, "header_text": "Six Months endedThree Months endedSix Months endedThree Months ended"}, {"table_index": 920, "table_type": "text", "caption": null, "header_text": "Weightedaverageexercise priceNumberof optionsWeightedaverageremaining contractuallife (in years)"}, {"table_index": 923, "table_type": "text", "caption": null, "header_text": "Number of RSAs"}, {"table_index": 924, "table_type": "text", "caption": null, "header_text": ""}, {"table_index": 926, "table_type": "text", "caption": null, "header_text": "Six Months endedJune 30,Six Months endedJune 30,"}, {"table_index": 927, "table_type": "financial", "caption": null, "header_text": "Six Months endedThree Months endedSix Months endedThree Months ended"}, {"table_index": 928, "table_type": "financial", "caption": null, "header_text": "Six Months endedThree Months endedSix Months endedThree Months ended"}, {"table_index": 933, "table_type": "financial", "caption": null, "header_text": "Report of Independent Registered Public Accounting FirmF-47"}, {"table_index": 935, "table_type": "text", "caption": null, "header_text": "\u25cfWe\n obtained and read the 2025 Notes agreements and obtained an understanding of the key terms,\n including the triggering events and other contractual terms, as applicable."}, {"table_index": 937, "table_type": "financial", "caption": null, "header_text": "December 31,"}, {"table_index": 939, "table_type": "financial", "caption": null, "header_text": "Year Ended December 31,"}, {"table_index": 941, "table_type": "financial", "caption": null, "header_text": "RedeemableConvertiblePreferred StockCommon StockAdditionalPaid inAccumulatedTotalStockholders\u2019"}, {"table_index": 943, "table_type": "financial", "caption": null, "header_text": "Year Ended December 31,"}, {"table_index": 950, "table_type": "text", "caption": null, "header_text": "DescriptionUseful\n life"}, {"table_index": 956, "table_type": "financial", "caption": null, "header_text": "December 31,"}, {"table_index": 957, "table_type": "financial", "caption": null, "header_text": "December 31,"}, {"table_index": 960, "table_type": "text", "caption": null, "header_text": "Year ended December 31,"}, {"table_index": 961, "table_type": "text", "caption": null, "header_text": "Year Ended December 31,"}, {"table_index": 964, "table_type": "financial", "caption": null, "header_text": "Fair Value Measurements at December 31, 2025"}, {"table_index": 965, "table_type": "financial", "caption": null, "header_text": "Fair Value Measurements at December 31, 2024"}, {"table_index": 967, "table_type": "text", "caption": null, "header_text": "Balance, January 1, 2024$-"}, {"table_index": 968, "table_type": "text", "caption": null, "header_text": "September 4, 2024December 31, 2024February 28, 2025June 30, 2025July 31,2025December 31, 2025"}, {"table_index": 971, "table_type": "text", "caption": null, "header_text": "December 31,"}, {"table_index": 973, "table_type": "financial", "caption": null, "header_text": "December 31,"}, {"table_index": 976, "table_type": "financial", "caption": null, "header_text": "December 31,"}, {"table_index": 977, "table_type": "text", "caption": null, "header_text": "Year ending December 31,"}, {"table_index": 979, "table_type": "text", "caption": null, "header_text": "December 31,"}, {"table_index": 985, "table_type": "text", "caption": null, "header_text": "Amounts at December 31, 2025"}, {"table_index": 986, "table_type": "text", "caption": null, "header_text": "Amounts at December 31, 2024"}, {"table_index": 989, "table_type": "text", "caption": null, "header_text": "December 31, 2025"}, {"table_index": 990, "table_type": "text", "caption": null, "header_text": "December 31, 2024"}, {"table_index": 993, "table_type": "text", "caption": null, "header_text": "Number ofOptionsWeighted-AverageExercise PricePer ShareWeighted-AverageRemainingContractualTerm (in years)AggregateIntrinsicValue (inthousands)"}, {"table_index": 994, "table_type": "text", "caption": null, "header_text": "Year Ended December 31,"}, {"table_index": 995, "table_type": "text", "caption": null, "header_text": "December 31,"}, {"table_index": 999, "table_type": "financial", "caption": null, "header_text": "Year Ended December 31,"}, {"table_index": 1000, "table_type": "financial", "caption": null, "header_text": "December 31,"}, {"table_index": 1002, "table_type": "text", "caption": null, "header_text": "Year Ended December 31,"}, {"table_index": 1004, "table_type": "text", "caption": null, "header_text": "Year Ended December 31,"}, {"table_index": 1009, "table_type": "financial", "caption": null, "header_text": "Year ended December 31,"}, {"table_index": 1014, "table_type": "financial", "caption": null, "header_text": "Condensed Balance SheetsF-80"}, {"table_index": 1016, "table_type": "financial", "caption": null, "header_text": "June 30,2026December 31,2025"}, {"table_index": 1018, "table_type": "financial", "caption": null, "header_text": "Six Months Ended June 30,"}, {"table_index": 1020, "table_type": "financial", "caption": null, "header_text": "Six Months Ended June 30, 2026"}, {"table_index": 1021, "table_type": "text", "caption": null, "header_text": "Six Months Ended June 30, 2025"}, {"table_index": 1023, "table_type": "financial", "caption": null, "header_text": "Six Months Ended June 30,"}, {"table_index": 1030, "table_type": "financial", "caption": null, "header_text": "Six Months Ended June 30,"}, {"table_index": 1031, "table_type": "financial", "caption": null, "header_text": "Six Months Ended June 30,"}, {"table_index": 1032, "table_type": "text", "caption": null, "header_text": "Six Months Ended June 30,"}, {"table_index": 1034, "table_type": "text", "caption": null, "header_text": "Six Months Ended June 30,"}, {"table_index": 1037, "table_type": "financial", "caption": null, "header_text": "Fair Value Measurements at June\n 30, 2026"}, {"table_index": 1038, "table_type": "financial", "caption": null, "header_text": "Fair Value Measurements at December\n 31, 2025"}, {"table_index": 1039, "table_type": "text", "caption": null, "header_text": "Balance, January 1, 2026$35,200"}, {"table_index": 1040, "table_type": "text", "caption": null, "header_text": "Balance, January 1, 2025$8,387"}, {"table_index": 1042, "table_type": "text", "caption": null, "header_text": "December 31,2024February 28,2025June 30,2025December 31,2025March 5,2026June 30,2026"}, {"table_index": 1044, "table_type": "financial", "caption": null, "header_text": "June\n 30,2026December\n 31,2025"}, {"table_index": 1047, "table_type": "financial", "caption": null, "header_text": "June 30,"}, {"table_index": 1050, "table_type": "text", "caption": null, "header_text": "June\n 30,2026December\n 31,2025"}, {"table_index": 1056, "table_type": "text", "caption": null, "header_text": "Number ofOptionsWeighted-AverageExercise\n PricePer ShareWeighted-AverageRemainingContractualTerm (in years)AggregateIntrinsicValue\n (inthousands)"}, {"table_index": 1057, "table_type": "text", "caption": null, "header_text": "Six Months Ended June 30,"}, {"table_index": 1063, "table_type": "financial", "caption": null, "header_text": "Six Months Ended June 30,"}, {"table_index": 1068, "table_type": "financial", "caption": null, "header_text": "Page"}, {"table_index": 1070, "table_type": "financial", "caption": null, "header_text": "Section\n 3.20 Insurance46"}, {"table_index": 1072, "table_type": "text", "caption": null, "header_text": "Article V. Certain Covenants of the Parties72"}, {"table_index": 1074, "table_type": "financial", "caption": null, "header_text": "Article VIII. Additional Conditions Precedent to Obligations of the Chemomab Entities94"}, {"table_index": 1075, "table_type": "exhibit_index", "caption": null, "header_text": "Exhibit AForm of Chemomab Shareholder Support Agreement"}, {"table_index": 1117, "table_type": "exhibit_index", "caption": null, "header_text": "TermSection"}, {"table_index": 1120, "table_type": "text", "caption": null, "header_text": "Closing\n DateSection\n 2.3"}, {"table_index": 1291, "table_type": "text", "caption": null, "header_text": "CHEMOMAB\n THERAPEUTICS LTD."}, {"table_index": 1295, "table_type": "financial", "caption": null, "header_text": "1.5.1.Without\n derogating from Section 323 of the Companies Law, as of the Domestication Merger Effective\n Date, (i) all assets, liabilities, licenses, permissions and agreements, including any tangib"}, {"table_index": 1303, "table_type": "text", "caption": null, "header_text": "4.1.1.The\n conditions set forth in Section 7.2 (No Restraints), Section 7.3 (Shareholder Approval),\n Section 7.4 (Regulatory Matters) (to the extent required to be satisfied prior to\n the Domesticatio"}, {"table_index": 1307, "table_type": "text", "caption": null, "header_text": "Chemomab Therapeutics Ltd."}, {"table_index": 1308, "table_type": "text", "caption": null, "header_text": "Snowdrift Parent Corporation"}, {"table_index": 1309, "table_type": "text", "caption": null, "header_text": "Elderwood Ltd."}, {"table_index": 1313, "table_type": "text", "caption": null, "header_text": "Chemomab\n Therapeutics Ltd."}, {"table_index": 1316, "table_type": "text", "caption": null, "header_text": "Chemomab\n Therapeutics Ltd."}, {"table_index": 1325, "table_type": "text", "caption": null, "header_text": "Scipher Medicine Corporation"}, {"table_index": 1328, "table_type": "text", "caption": null, "header_text": "Page"}, {"table_index": 1330, "table_type": "financial", "caption": null, "header_text": "Page"}, {"table_index": 1363, "table_type": "text", "caption": null, "header_text": "h)reviewed\n other public information concerning each of the Company and Chemomab;"}, {"table_index": 1366, "table_type": "text", "caption": null, "header_text": "Very\n truly yours,"}, {"table_index": 1431, "table_type": "text", "caption": null, "header_text": "Date:December\n 4,2026"}, {"table_index": 1433, "table_type": "text", "caption": null, "header_text": ""}, {"table_index": 1435, "table_type": "text", "caption": null, "header_text": "\u25cfMark,\n sign and date your Voting Instruction Form."}, {"table_index": 1436, "table_type": "text", "caption": null, "header_text": "PROXY\n TABULATOR FOR"}, {"table_index": 1437, "table_type": "text", "caption": null, "header_text": "EVENT\n #"}], "exhibits_pending": false, "cdn_html": true, "response_time_ms": 49}